New hope for kidney cancer: experimental drug AB521 enters human testing

NCT ID NCT05536141

Recruiting now Disease control Sponsor: Arcus Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated Apr 28, 2026 · Updated 25 times

Summary

This early-phase study tests a new drug called AB521 (casdatifan) in people with advanced kidney cancer or other solid tumors that have not responded to standard treatments. The study will first find a safe dose of AB521 alone, then test it alone or combined with other cancer drugs. About 362 participants will be enrolled to check safety, side effects, and how the drug moves through the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Asan Medical Center
RECRUITING

Seoul, South Korea
Ashford Cancer Centre Research/ICON
RECRUITING

Sydney, Australia
Barbara Ann Karmanos Cancer Center
RECRUITING

Detroit, Michigan, 48201, United States
Box Hill Hospital
NOT_YET_RECRUITING

Melbourne, Australia
Chris O'Brien Lifehouse
NOT_YET_RECRUITING

Camperdown, Australia
Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Emory University
RECRUITING

Atlanta, Georgia, 30322-1013, United States
Henry Ford Health System
RECRUITING

Detroit, Michigan, 48202, United States
Macquarie University Hospital
RECRUITING

Sydney, Australia
Memorial Sloan Kettering
RECRUITING

New York, New York, 10065, United States
Nebraska Cancer Specialists - Oncology Hematology West PC
RECRUITING

Omaha, Nebraska, 68124, United States
Oschner Health
RECRUITING

New Orleans, Louisiana, 70121, United States
Samsung Medical Center
RECRUITING

Seoul, South Korea
Sarah Cannon
RECRUITING

Nashville, Tennessee, 37203, United States
Seoul National University Bundang Hospital
RECRUITING

Seoul, South Korea
Severance Hospital
RECRUITING

Seoul, South Korea
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RECRUITING

Baltimore, Maryland, 21287, United States
South Texas Accelerated Research Therapeutics, LLC
RECRUITING

San Antonio, Texas, 78229, United States
Tisch Cancer Institute, Icahn Mount Sinai Hospital
RECRUITING

New York, New York, 10029, United States
UCLA
RECRUITING

Santa Monica, California, 90404, United States
UPMC Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
University Hospitals Cleveland Clinical
RECRUITING

Cleveland, Ohio, 44106, United States
University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35294, United States
University of California at San Diego
RECRUITING

San Diego, California, 92093, United States
University of Louisville Brown Cancer Center
RECRUITING

Louisville, Kentucky, 40202, United States
University of Miami
RECRUITING

Miami, Florida, 33136, United States
Vall d'Hebron Institute of Oncology (VHIO)
NOT_YET_RECRUITING

Barcelona, Spain
Vanderbilt-Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37240, United States

Conditions

Explore the condition pages connected to this study.

CLEAR CELL RENAL CELL CARCINOMA SOLID TUMORS SOLID TUMORS